These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 19075685)
1. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies. Chartrain M; Chu L Curr Pharm Biotechnol; 2008 Dec; 9(6):447-67. PubMed ID: 19075685 [TBL] [Abstract][Full Text] [Related]
5. "Antibodies--Europe. Engineering the next generation of antibodies". Moutel S; Perez F Biotechnol J; 2008 Mar; 3(3):298-300. PubMed ID: 18348242 [No Abstract] [Full Text] [Related]
6. Development trends for therapeutic antibody fragments. Nelson AL; Reichert JM Nat Biotechnol; 2009 Apr; 27(4):331-7. PubMed ID: 19352366 [No Abstract] [Full Text] [Related]
7. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Beck A; Wagner-Rousset E; Bussat MC; Lokteff M; Klinguer-Hamour C; Haeuw JF; Goetsch L; Wurch T; Van Dorsselaer A; Corvaïa N Curr Pharm Biotechnol; 2008 Dec; 9(6):482-501. PubMed ID: 19075687 [TBL] [Abstract][Full Text] [Related]
8. New technologies in therapeutic antibody development. Brekke OH; Løset GÅ Curr Opin Pharmacol; 2003 Oct; 3(5):544-50. PubMed ID: 14559101 [TBL] [Abstract][Full Text] [Related]
9. Protein Engineering for Biotherapeutics--IBC's second annual conference. Developing and improving next generation biotherapeutics. Smider V IDrugs; 2007 Mar; 10(3):176-7. PubMed ID: 17351870 [No Abstract] [Full Text] [Related]
10. [Biologics--the new horizon for medical therapy]. Ziegenhagen DJ Versicherungsmedizin; 2009 Mar; 61(1):4-9. PubMed ID: 19370838 [TBL] [Abstract][Full Text] [Related]
11. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
12. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle. Haurum J; Bregenholt S IDrugs; 2005 May; 8(5):404-9. PubMed ID: 15883923 [TBL] [Abstract][Full Text] [Related]
13. Design and manufacture of monoclonal antibodies for radioimmunotherapy. Hale G; Berrie E; Bird P Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789 [TBL] [Abstract][Full Text] [Related]
14. The growth and potential of human antiviral monoclonal antibody therapeutics. Marasco WA; Sui J Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic antibodies and other proteins obtained by molecular display technologies. Shibasaki S; Ueda M Recent Pat Biotechnol; 2009; 3(1):19-27. PubMed ID: 19149719 [TBL] [Abstract][Full Text] [Related]
16. Looking forward in pharmaceutical process chemistry. Davies IW; Welch CJ Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417 [TBL] [Abstract][Full Text] [Related]
17. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. Niwa R; Satoh M J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555 [TBL] [Abstract][Full Text] [Related]
18. Commercial proteases: present and future. Li Q; Yi L; Marek P; Iverson BL FEBS Lett; 2013 Apr; 587(8):1155-63. PubMed ID: 23318711 [TBL] [Abstract][Full Text] [Related]